BJDXHealthcare · Medical DevicesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 8 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Bluejay Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Value (2): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BJDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2023 | Dawson James | Downgrade | Neutral | — |
| 12 Jan 2022 | Dawson James | Initiates | Buy | $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BJDX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Bluejay Diagnostics, Inc. returned −89.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Cheaper than 89% of US stocks
Cheaper than 58% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 13% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bluejay Diagnostics, Inc. has a market value of $3.6M and an enterprise value of −$5.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$7.3M.
Free cash flow in the twelve months to 30 June 2026: −$6.2M.
Trailing P/E: 0.0×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Bluejay Diagnostics, Inc. employs 6 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bluejay Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bluejay Diagnostics said it revealed foundational clinical data from its SYMON-II validation trial for its Symphony near-patient diagnostic platform.
Why it matters — The trial data relates to Bluejay’s platform for rapid biomarker testing in sepsis patients.
Bluejay Diagnostics reported preliminary baseline characteristics from its SYMON-II clinical validation study, including 777 evaluable patients: 637 28-day survivors and 140 non-survivors. The overall 28-day mortality rate was approximately 18%, and the study is evaluating IL-6 as a biomarker associated with mortality risk in sepsis and septic shock.
Why it matters — The dataset is a milestone in Bluejay’s evaluation of the Symphony IL-6 Test as the company advances it toward regulatory submission.
Bluejay Diagnostics announced a partnership with Lovell Government Services to establish a federal distribution and co-marketing framework aimed at expanding access to U.S. federal healthcare markets, including the VA, DoD, and Military Health Systems, as well as other government healthcare channels.
Why it matters — This partnership could open new government distribution channels for Bluejay Diagnostics, potentially broadening its market reach within the federal healthcare sector.
Bluejay Diagnostics reported its financial results for the quarter ended June 30, 2026, and provided an update on its clinical, regulatory and manufacturing progress. The company said its strengthened balance sheet supports advancement of the Symphony™ IL-6 test toward regulatory submission and commercialization.
Why it matters — A BJDX watcher would care because the update addresses the company's clinical, regulatory and manufacturing progress toward bringing Symphony™ IL-6 to regulatory submission and commercialization.
As at 8 Oct 2026, Bluejay Diagnostics, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No analyst covering Bluejay Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BJDX are extrapolating price history, which says nothing about the business.
Bluejay Diagnostics, Inc. returned -89.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings.
The most recent item we track (Benzinga, 6 Oct 2026): "Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients". Bluejay Diagnostics said it revealed foundational clinical data from its SYMON-II validation trial for its Symphony near-patient diagnostic platform.
Bluejay Diagnostics Inc. is a medical diagnostics company focused on rapid, near-patient testing solutions for critical care and other clinical settings. Its core Symphony platform combines an analyzer and single-use cartridges to process whole blood and detect key biomarkers, supporting timely assessment of inflammation, infection, and cardiac conditions. The company’s current product development includes the Symphony IL-6 test for monitoring disease progression in critical care, along with additional assays targeting myocardial infarction and congestive heart failure. Bluejay Diagnostics also develops point-of-care diagnostic products designed to give healthcare providers faster, practical insights at the bedside. Headquartered in Acton, Massachusetts, Bluejay Diagnostics Inc. serves the healthcare market through technologies aimed at improving diagnostic workflows and supporting informed clinical decision-making.
CEO Mr. Indranil Dey · 6 employees · United States · https://bluejaydx.com
